LGC, has concluded a licensing agreement with Falco biosystems that gives Falco rights to the CYP2D64 genetic polymorphism patent (Patent No 3272353) in Japan.
LGC is the exclusive licensor of this gene variation on behalf of Dundee University and Cancer Research UK.
The analysis of Cytochrome P450 genetic polymorphisms plays an important role in pharmacogenetics where it can be used to predict drug metabolism and adverse drug reactions.
Variations in genes such as CYP2D6 gene can affect an individual's ability to metabolise many common drugs including painkillers, anti-depressants and cardiovascular drugs with implications in both drug development and therapy.
Falco formed a business alliance with Gentris Corporation (Morrisville, North Carolina US) in August 2006 and will provide pharmacogenetic services to the Japanese pharmaceutical market based on its know-how.
